search
cancer treatment
Trends
- 113-Year-Old Reported Cured of DIPG, Deadliest Childhood Brain CancerโA 13-Year-Old Has Been Cured of DIPG, the Deadliest Childhood Brain Cancer
A 13-year-old has reportedly become the first person cured of DIPG, an incurable and almost universally fatal childhood brain cancer. News of the case, described as a world first, has spread widely online, with readers reacting to the prospect of a breakthrough against a disease that has long defied treatment and typically claims young patients' lives within months of diagnosis.
- 2
A melanoma vaccine built on mRNA technology is in the news, with health outlets highlighting it as a promising new approach to treating the deadliest form of skin cancer. mRNA vaccines, proven at scale during the COVID-19 pandemic, are being developed to train the immune system to recognise and attack cancer cells, with several candidates now in clinical trials.
- 3CAR T cell therapy shows two years free of lupus flaresโTwo years later, CAR T cell therapy shows promise for life without lupus flares
Researchers at UMass Chan Medical School report that lupus patients treated with CAR T cell therapy have remained free of disease flares two years after receiving the one-time cell-based treatment. The therapy, originally developed for blood cancers, reprograms a patient's own immune cells, and the latest follow-up data suggest it may offer lasting remission in autoimmune disease.
- 4Proliferative Pause Offers Window to Prevent Brain MetastasisโProliferative Pause Reveals Window to Prevent Brain Metastasis
Researchers report that cancer cells entering a 'proliferative pause' โ a dormant, slow-dividing state โ may expose a critical window during which brain metastasis could be prevented. The finding suggests that targeting cells during this quiescent phase, before they resume growth in the brain, could open new preventive strategies against one of the deadliest consequences of cancer spread.
- 5Penn Medicine and IBA Launch Proton Therapy Joint VentureโPenn Medicine, IBA Form Joint Venture to Advance Proton Therapy, Radiation Oncology
Penn Medicine and Belgian medical technology company IBA have formed a joint venture aimed at advancing proton therapy and radiation oncology. The partnership will combine Penn Medicine's clinical expertise with IBA's technology to develop and expand proton therapy treatments for cancer patients.